Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX13 vs YERVOY in Unresectable Hepatocellular Carcinoma
NCT06841185Phase 3Not yet recruiting
- Sponsor
- Henlius
- Start
- Apr 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of HLX13 in hepatocellular carcinoma (HCC), sponsored by Henlius. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
HLX13
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06841185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841185.